Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis

PLoS One. 2013 Dec 27;8(12):e84218. doi: 10.1371/journal.pone.0084218. eCollection 2013.

Abstract

Background: Nasopharyngeal carcinoma (NPC) is known for its high metastatic potential and locoregional recurrence, although the molecular alterations that are driving NPC metastasis remain unclear at this time. This study aimed to examine the expression of fibulin-5 in NPC, correlate the results with clinicopathological variables and survival, and to investigate the role of fibulin-5 in human NPC cell lines.

Material and methods: Standard semi-quantitative-RT-PCR, quantitative-RT-PCR, immunoblotting, and immunohistochemistry were used to investigate the mRNA and protein expression profiles of fibulin-5 in normal and NPC tissues. Immunohistochemistry of fibulin-5 was correlated with clinicopathological characteristics by univariate analyses. NPC cells overexpressing fibulin-5 or fibulin-5-siRNA cells were generated by stable transfection to characterize the molecular mechanisms of fibulin-5-elicited cell growth and metastasis.

Results: Our results demonstrated that fibulin-5 overexpression in NPC specimens and significantly correlated with advanced tumor metastasis indicating a poor 5-year overall survival. Fibulin-5 was mainly expressed in the nucleus in human NPC specimens and cell lines. Functionally, fibulin-5 overexpression yielded fast growth in NPC cells. In addition, fibulin-5 promotes cell metastasis in NPC cells through increased FLJ10540 and phosphor-AKT activity. In contrast, siRNA depletion of fibulin-5 suppressed FLJ10540 expression and phosphor-AKT activity. Suppression of either fibulin-5 or FLJ10540 can cause significant inhibition with regards to cell motility in NPC cells. Finally, immunohistochemical analysis of human aggressive NPC specimens showed a significant and positive correlation between fibulin-5 and FLJ10540 expression.

Conclusion: Higher fibulin-5 expression is not only an important indicator of poor survival, but also contributes to the development of new therapeutic strategies in the FLJ10540/AKT pathway for NPC treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Retracted Publication

MeSH terms

  • Active Transport, Cell Nucleus
  • Carcinoma
  • Cell Cycle Proteins / metabolism*
  • Cell Line, Tumor
  • Cell Movement
  • Cell Nucleus / metabolism
  • Cell Proliferation
  • Disease Progression
  • Extracellular Matrix Proteins / deficiency
  • Extracellular Matrix Proteins / genetics*
  • Extracellular Matrix Proteins / metabolism
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Knockdown Techniques
  • Humans
  • Male
  • Middle Aged
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms / diagnosis*
  • Nasopharyngeal Neoplasms / genetics
  • Nasopharyngeal Neoplasms / metabolism
  • Nasopharyngeal Neoplasms / pathology*
  • Neoplasm Invasiveness
  • Neoplasm Metastasis
  • Nuclear Proteins / metabolism*
  • Oncogenes*
  • Prognosis
  • Proto-Oncogene Proteins c-akt / metabolism*
  • RNA, Small Interfering / genetics
  • Signal Transduction*
  • Survival Analysis

Substances

  • Cell Cycle Proteins
  • Cep55 protein, human
  • Extracellular Matrix Proteins
  • FBLN5 protein, human
  • Nuclear Proteins
  • RNA, Small Interfering
  • Proto-Oncogene Proteins c-akt

Grants and funding

This study was funded by grants obtained by Dr. Chung-Feng Hwang (CMRPG890461-2, CMRPG8A0871, NSC 98-2314-B-182A-046-MY3 (NMRPG886051-3), NSC 101-2314-B-182A-138 (NMRPG8B0214), and NSC 102-2314-B-182A-115 (NMRPG8C0271)), and by Dr. Chang-Han Chen (CMRPG8A0391-2, CMRPG890921, CMRPG8B1251, NSC 100-2320-B-182A-001 (NMRPG8A0011), and NSC 102-2320-B-182A-010 (NMRPG8C0141)). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.